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Abstract 2',3'-Dideoxyadenosine (ddA), 2',3'-didehydro-2',3'-
dideoxyadenosine (d4A) and their lipophilic 5'-monophosphate 
triester (aryloxyphosphoramidate) prodrugs were evaluated for 
their anti-retrovirus and anti-hepatitis B virus activity in various 
cell culture models. The aryloxyphosphoramidate derivatives of 
ddA (Cf 1093) and d4A (Cf 1001) showed markedly superior 
(100-1000-fold) efficacies than the parent drugs against human 
immunodeficiency virus type 1 (HIV-1), HIV-2, simian immu-
nodeficiency virus (SIV), Moloney murine sarcoma virus (MSV) 
and human hepatitis B virus (HBV) replication regardless of the 
cell type in which the virus replication was studied (i.e., human T-
lymphocyte CEM, MT-4, Molt/4 and C8166 cells, peripheral 
blood lymphocytes (PBL), monocyte/macrophages (M/M), 
murine embryo fibroblasts and human hepatocyte cells). Also 
the selectivity index (ratio of cytotoxic concentration/antivirally 
effective concentration) of both aryloxyphosphoramidate pro-
drugs was markedly increased. In particular the d4A prodrug Cf 
1001 showed a selectivity index of 300-3000 as compared with 2 -
3 for the parental d4A in established laboratory cell lines. Also 
Cf 1001 had a selectivity index of 400-650 in HIV-1-infected 
PBL and M/M, respectively. Both Cf 1001 and Cf 1093 were 
equally efficient as 3TC (lamivudine) in inhibiting HBV 
replication in hepatocytes, and rank among the most potent 
HIV and HBV inhibitors reported so far in cell culture. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Nucleoside analogues that are active against human immu-
nodeficiency virus (HIV) need to be converted to their corre-
sponding 5'-triphosphate derivatives before they can inhibit 
their target enzyme (reverse transcriptase). The first activation 
(phosphorylation) step is predominantly catalysed by nucleo-
side kinases and/or 5'-nucleotidases [1-6]. Except for AZT, 
most anti-HIV-active nucleoside analogues have a relatively 
poor affinity for their activating enzymes [2,3,6-10]. In an 
attempt to circumvent the first phosphorylation step, several 
types of masked (lipophilic) nucleoside 5'-monophosphate 
*Corresponding author. Fax: (32) (16) 337-340. 
prodrugs have been synthesized (containing two phosphate 
blocking groups such as bis(pivaloyloxymethyl) (bis(POM)), 
bis(5-acyl-2-thioethyl) (bis(SATE)), dioxophosphorine oxide 
and bis(isopropyloxycarbonyloxymethyl) (bis(POC))) [11-18]. 
Recently, we reported the synthesis and anti-retrovirus activ-
ity of the masked alaninylphosphoramidate 2',3'-didehydro-
2',3'-dideoxythymidine 5'-monophosphate (d4T-MP) prodrug 
(designated So324), and showed that it retains full anti-HIV 
activity in thymidine-kinase-deficient CEM/TK~ cells [19,20]. 
These findings strongly suggested that the phosphotriester 
prodrug of d4T efficiently released the intact phosphorylated 
metabolite d4T-MP inside the HIV-infected cells, thereby cir-
cumventing the first activation (phosphorylation) step [19,20]. 
So324 proved poorly effective against human hepatitis B virus 
(HBV) replication in human hepatoma cells (21). In contrast, 
the corresponding 3TC aryloxyphosphoramidate derivative 
was very effective against HBV replication in human hepato-
ma cells, but only marginally effective against HIV in human 
T-lymphocytes [21]. Given the striking differences in antiviral 
efficacy of the thymine and cytosine nucleoside aryloxyphos-
phoramidate prodrugs in T-lymphocytes and hepatoma cells, 
we now investigated the antiviral activity of the 2',3'-dideoxy-
adenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine 
(d4A) aryloxyphosphoramidate prodrugs. Both compounds 
proved exquisitely inhibitory to both HIV and HBV in cell 
culture and showed a markedly higher antiviral selectivity in-
dex than their parental ddA and d4A. 
2. Materials and methods 
2.1. Viruses 
HIV-I(IIIB) and HIV-2(ROD) were kindly provided by Prof. R.C. 
Gallo (when being at the National Cancer Institute (NCI), National 
Institutes of Health, Bethesda, MD, USA) and Dr. L. Montagnier 
(Pasteur Institute, Paris, France). HIV-1/Ba-L was a gift from Dr. 
M. Popovic and Dr. R.C. Gallo (NCI, NIH). SIV (MAC23i) was 
kindly provided by Dr. J. Slachmuylders and H. Schellekens (when 
at the TNO Primate Center, Rijswijk, The Netherlands). 
2.2. Cells 
CEM cells were obtained from the American Tissue Cell Culture 
Collection (Rockville, MD, USA); and MT-4, Molt 4/clone 8 and 
C8166 cells were kindly provided by Dr. N. Yamamoto (Nagoya 
Memorial Hospital, Nagoya, Japan), Dr. H. Nakashima (Kagoshima 
University Dental School, Kagoshima, Japan) and Dr. P. La Colla 
(Universita degli Studi di Cagliari, Cagliari, Italy, respectively). Hep 
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G2 2.2.15 hepatoblastoma cells were provided by Dr. G. Acs (Mount 
Sinai Medical Center, NY, USA). 
2.3. Compounds 
The aryloxyphosphoramidate prodrug of d4A (designated Cf 1001) 
has been synthesized as described before [22]. The detailed synthesis of 
the aryloxyphosphoramidate prodrug of ddA (designated Cf 1093) 
(Fig. 1) will be described elsewhere. We have designed the prodrug 
synthesis occurring in one high-yielding (85-95%) step under mild 
conditions using readily available starting materials (i.e., alanine and 
phenol) and resulting in d4A and ddA aryloxyphosphoramidate de-
rivatives that should be not markedly more expensive than the de 
novo synthesis of d4A and ddA. 
2.4. Antiviral activity of the test compounds 
CEM, MT-4, Molt 4/clone 8 and C8166 cells were suspended at 
250000-350000 cells per ml of culture medium and infected with 
approximately 100 CCID60 (1 CCID50 being the 50% cell culture 
infective dose) of HiV-l(IIIB) or HIV-2(ROD). Then, 100 ul of the 
infected cell suspensions was added to 200-ul-microtiterplate wells 
containing 100 ul of an appropriate dilution of the test compounds 
(i.e., 250, 100, 20, 4, 0.8, 0.16, 0.032, 0.006, 0.001 uM). The inhibitory 
effect of the test compounds on HIV-1-induced syncytium formation 
in CEM, Molt 4 and C8166 cells was examined on day 4 post-infec-
tion, and their inhibitory effect on the viability of HIV-infected MT-4 
cells was examined on day 5 post-infection, as described previously 
[20], The 50% effective concentration (EC50) was determined as the 
compound concentration required to inhibit syncytium formation 
(CEM, Molt 4, C8166) or to reduce cell viability (MT-4) by 50%. 
The 50% cytostatic concentration (CC50) was defined as the com-
pound concentration required to reduce cell viability or cell prolifer-
ation by 50%. 
Peripheral blood lymphocyte cells (PBL) were isolated from a 
healthy HIV-1-negative human volunteer by using lymphoprep, 
washed twice with phosphate-buffered saline (PBS) and cultured 
with phytohemagglutinin (PHA, 2 |Xg/ml) and interleukin-2 (10 U/ 
ml) for 3 days at 37°C in a CO2-controlled humidified incubator. 
Stimulated PBMCs were washed twice with PBS and then infected 
with HIV-1 ( H T L V - I I I B ) at 1000 CCID50 per ml in RPMI-1640 me-
dium supplemented with 15% heat-inactivated foetal calf serum, L-
glutamine (2 mM), gentamicin (50 ug/ml), and recombinant interleu-
kin-2 (10 U/ml). After 60 min incubation at 37°C, non-adsorbed virus 
was removed by successive washing steps with fresh culture medium, 
and the HIV-1-infected PBLs were suspended at 5X105 cells/ml in 
RPMI-1640 medium and cultured in the presence of varying concen-
trations (20, 4, 0.8, 0.16, 0.032 and 0.006 uM) of the test compounds 
in 96-well culture plates (200 ul per well). At day 4, all cultures were 
subcultivated. HIV-1 p24 core antigen was quantified in the cell 
culture supernatants at 7 days after infection by an antigen-capture 
ELISA (DuPont). 
Human primary macrophages were obtained from blood of healthy 
seronegative donors by countercurrent centrifugal elutriation, fol-
lowed by treatment for 7 days with 1000 U/ml macrophage colony 
stimulating factor (M-CSF). Macrophages were then treated with var-
ious concentrations of drugs, and 30 min after being challenged with 
300 50% tissue culture infectious doses (TCID50/ml) of the monocyto-
tropic BaL strain, virus production was then assessed at 14 days after 
infection by a commercially available p24 antigen-capture assay, and 
by syncytium formation. The experimental details of the technique are 
described elsewhere [23]. 
For analysis of extracellular HBV DNA Hep G2 2.2.15 hepatoblas-
toma cells were seeded in cell culture recipients as described before 
[24]. After seeding, culture medium containing the drugs was changed 
at days 3, 6 and 9. At day 12, the culture medium was harvested and 
clarified by centrifugation for determination of HBV DNA. The cul-
ture supernatants were prepared for dot blot analysis according to 
Korba and Milman [25] and applied to Hybon N+ membranes 
(Amersham Life Science Prodcuts) in the Convertible Filtration Mani-
fold System (BRL, Life Technologies). 
3. Results 
3.1. Antiretroviral activity of test compounds in established 
laboratory cell lines 
ddA, d4A, ddl and the aryloxyphosphoramidate prodrugs 
of ddA and d4A were evaluated for their antiviral efficacy 
against human immunodeficiency virus type 1 (HIV-1), 
HIV-2, simian immunodeficiency virus (SIV) and Moloney 
murine sarcoma virus (MSV) in a variety of cell culture mod-
els including MT-4, CEM, Molt 4, C8166 and C3H (Table 1). 
ddA and ddl were inhibitory to HIV-1, HIV-2, SIV and MSV 
at 50% effective concentrations that ranged between 2.7 and 
10 |iM in CEM, MT-4, Molt 4 and C3H cell cultures. The 
anti-HIV-1 and -HIV-2 activity of both reference compounds 
was somewhat lower in C8166 cell cultures (EC50: 12-22 |xM). 
The 2',3'-unsaturated d4A was approximately 5-10-fold less 
effective than ddA (EC50: 21->50) regardless of the nature of 
the cell line. The aryloxyphosphoramidate derivatives of ddA 
(Cf 1093) and d4A (Cf 1001) were highly inhibitory to all 
retroviruses tested, irrespective of the nature of the cell line 
used. Their EC50 ranged from 0.007 to 0.065 uM, that is an 
EC50 that was at least 2 to more than 3 orders of magnitude 
lower than that required for the parent ddA and d4A deriv-
atives. Whereas ddl and ddA were virtually devoid of cyto-
static activity in cell culture at 250 u\M, d4A was cytostatic at 
a CC50 of 49-97 uM. Cf 1093 showed a markedly increased 
toxicity over ddA (CC50: 6.6-15 uM), but Cf 1001 was only 
3-5-fold more cytostatic to cell proliferation than d4A. Con-
sequently, the selectivity indices (S.I. or ratio CC50/EC5o) of 
the aryloxyphosphoramidate derivatives of ddA and, in par-
ticular, d4A, were substantially increased. For example, whilst 
d4A had an S.I. of not more than 2 or 3 for HIV-1, HIV-2 
and SIV, its aryloxyphosphoramidate derivative Cf 1001 had 
a S.I. of 300-2500 (Table 1). 
3.2. Antiretroviral activity of test compounds in freshly isolated 
primary peripheral blood lymphocyte cells (PBL) and 
monocytelmacrophage (MIM) cell cultures 
The test compounds were also investigated for their antire-
troviral activity in freshly isolated peripheral blood lympho-
Table 1 
Cytostatic activity and inhibitory effect of ddA, Cf 2093, d4A, Cf 1001 and ddl on HIV replication in different human lymphocyte cell lines 
Compound 
ddA 
Cf1093 
d4A 
Cf 1001 
ddl 
E C 5 0
a 
MT-4 
HIV-1 
5.27 
0.010 
21 
0.007 
2.7 
(uM) 
SIV 
5.3 
0.006 
26 
0.008 
4.8 
CEM 
HIV-1 
4 
0.016 
20 
0.006 
2.2 
HIV-2 
8 
0.035 
20 
0.018 
-
Molt 4/C8 
HIV-1 
4 
0.016 
30 
0.030 
10 
HIV-2 
5.5 
0.050 
25 
0.040 
4.5 
C8166 
HIV-1 
17 
0.040 
>50 
0.055 
12 
HIV-2 
22 
0.050 
32 
0.065 
15 
C3H/3T3 
MSV 
24 
1.9 
31 
9.4 
-
CC50 
MT-4 
>250 
6.5 
49 
18 
>250 
(uM) 
Molt 4/C8 
>250 
6.8 
74 
16 
>250 
C8166 
>250 
15 
97 
19 
>250 
C3H/3T3 
>250 
>20 
£100 
>100 
>250 
B50% effective concentration, or compound concentration required to inhibit virus-induced cytopathology by 50%. 
b50% cytotoxic concentration, or compound concentration required to inhibit cell proliferation by 50%. 
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ddA d4A 
cr OCH3 
Cf 1093 CflOOl 
Fig. 1. Structural formulae of 2',3'-dideoxyadenosine (ddA), 2',3'-
didehydro-2',3'-dideoxyadenosine (d4A), and their corresponding ar-
yloxyphosphoramidate derivatives, Cf 1093 and Cf 1001. 
cyte cells (PBL) and monocyte/macrophage (M/M) cell cul-
tures. Similarly striking findings were found as obtained for 
the HIV-1-infected established laboratory cell lines (Table 2). 
The ddA aryloxyphosphoramidate derivative Cf 1093 proved 
120-fold more efficient than ddA as an inhibitor of HIV-1 
replication in PBLs and M/M, whilst the d4A aryloxyphos-
phoramidate derivative Cf 1001 proved > 100-300-fold more 
inhibitory than d4A to HIV-1 in M/M and PBLs. The toxicity 
of Cf 1093 and Cf 1001 was increased by > 5-12-fold in M/ 
M, but only 3-5-fold in PBLs, as compared to the parental 
ddA and d4A compounds, resulting in a pronounced in vitro 
selectivity index for the aryloxyphosphoramidate prodrugs in 
PBL and M/M. 
3.3. Antiviral activity of the test compounds against the 
extracellular release of HBVfrom HBV-transfected 
Hep G2 2.2.15 cell cultures 
The ddA, d4A and aryloxyphosphoramidate derivatives of 
ddA (Cf 1093) and d4A (Cf 1001) were also evaluated for 
their ability to inhibit extracellular HBV release in the super-
natant of Hep G2 2.2.15 cell cultures (Fig. 2). Both ddA and 
d4A lacked any efficacy against HBV at a concentration as 
high as 10 N,M (Fig. 2, upper panels). In contrast, Cf 1093 and 
Cf 1001 strongly inhibited HBV DNA release at drug concen-
trations between 1 and 10 u,M. Even at a concentration as low 
as 0.1 uM, Cf 1093 and, in particular, Cf 1001 were still able 
to partially suppress HBV release from the transfected cells. 
At 0.01 (tM, Cf 1093 and Cf 1001 had no marked inhibitory 
effect on HBV replication, as measured by dot-blot DNA 
analysis (Fig. 2, lower panels). Thus, the EC50 of Cf 1093 
and Cf 1001 for HBV replication could be estimated at 0 .1-
0.01 (tM, whereas the parent drugs ddA and d4A were com-
pletely ineffective against HBV at 100-1000-fold higher con-
centrations. 
4. Discussion 
We have recently reported a successful approach to deliver 
directly the 5'-monophosphate derivative of the anti-HIV 
drug d4T (stavudine) into intact cells by converting d4T to 
its aryloxyphosphoramidate analogue [19,20]. Studies with ra-
diolabeled test compound have revealed that substantial 
amounts of d4T-MP were delivered inside intact CEM cells 
upon exposure of the d4T aryloxyphosphoramidate derivative 
to the cells [26]. In addition, we have demonstrated that the 
extent of d4T-MP delivery in the intact cells is highly depend-
ent on the cell type used [20]. We have also shown that the 
3TC aryloxyphosphoramidate derivative was about 100-fold 
less active in HIV-infected T-lymphocytes as compared to the 
parent 3TC, while it retained the same efficacy as 3TC in 
inhibiting HBV in human hepatocytes [21]. 
Here, we have demonstrated that the purine nucleoside ar-
yloxyphosphoramidate derivatives, Cf 1093 and Cf 1001, ac-
quire significantly increased antiviral efficacy against both 
HIV in T-lymphocytes and HBV in hepatocytes. These favor-
able properties of the purine nucleoside aryloxyphosphorami-
dates are in marked contrast with our previous findings on the 
pyrimidine nucleoside aryloxyphosphoramidates where the 
3TC prodrug was not superior to 3TC against HBV in human 
hepatocytes and was even markedly inferior to 3TC against 
HIV in T-lymphocytes. These striking differences between the 
antiretroviral and anti-HBV efficacies of purine and pyrimi-
dine nucleoside aryloxyphosphoramidates presumably reflect 
differences in uptake and/or, more likely, intracellular conver-
sion of the prodrugs to their eventual active metabolites (i.e., 
the 5'-triphosphate derivatives). 
Indeed, we have previously shown that conversion of the 
aryloxyphosphoramidate d4T prodrug to d4T-TP is highly 
dependent on the nature of the cell type (or species) [20]. In 
this respect, human and sheep cell cultures were by far more 
effective than murine and feline cell cultures in generating 
d4T-TP from the d4T prodrug. In contrast, human serum 
and fetal calf serum are unable to efficiently hydrolyse the 
d4T aryloxyphosphoramidate derivative to its intermediate 
alaninyl-d4T-MP derivative, whereas murine serum fully hy-
drolyses the d4T prodrug to alaninyl d4T-MP within a short 
time period (L. Naesens, E. De Clercq, C. McGuigan and 
J. Balzarini, unpublished). Preliminary experiments revealed 
that the d4A and ddA prodrugs were efficiently converted 
by both human T-lymphocyte (CEM) and human hepatocyte 
cell extracts to their corresponding alaninyl nucleoside 
5'-monophosphate derivatives (data not shown). Since ester-
ase-catalysed conversion of the aryloxyphosphoramidate de-
rivatives to their alaninyl nucleoside 5'-monophosphate deriv-
atives are thought to be a prerequisite of further efficient 
intracellular release of the nucleoside 5'-monophosphate 
Table 2 
Cytostatic activity and inhibitory effect of ddA, Cf 1093, d4A and 
Cf 1001 on HIV-1 replication in peripheral blood lymphocytes and 
monocyte/macrophages 
Compound 
ddA 
Cf1093 
d4A 
Cf1001 
EC50 
PBL 
0.24 
0.002 
2.3 
0.008 
(uM) 
M/M 
1.0 
0.005 
5 
0.010 
CC50
 b (uM) 
PBL M/M 
24 >50 
4.6 10 
14 >50 
5.2 4 
S.I.C 
PBL 
100 
2300 
6.1 
650 
M/M 
>50 
2000 
>10 
400 
a50% effective concentration, or compound concentration required to 
achieve 50% reduction of the p24 antigen levels in the supernatant of 
HIV-1-infected peripheral blood lymphocyte cells (PBL) or monocyte/ 
macrophages (M/M). 
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Fig. 2. Evaluation of HBV DNA by dot blot hybridisation, from cell culture supernatants of Hep G2 2.2.15 after 12 days of incubation in the 
presence of varying drug concentrations. The cell cultures were exposed to ddA, d4A, Cf 1001, Cf 1093 or SddC (3TC) at 0 (upper horizontal 
row), 0.01, 0.1, 1.0 and 10 uM (lowest horizontal row). The experiment was performed in quadruplicate (vertical lanes). 
derivatives [26], these observations may explain the exquisite 
and superior activity of the d4A and ddA prodrugs against 
HIV and HBV, as compared to the parental d4A and ddA 
nucleosides. 
It should be noted that the experiments involving M/M 
were performed in the presence of M-CSF. Under these con-
ditions, 2'-deoxyadenosine analogues (i.e., ddA and ddl) are 
far less active than in M/M not treated with M-CSF, because 
of the increased dATP pools induced by this cytokine. The 
results obtained with ddA and d4A are in agreement with 
those previously described [23]. Under these unfavourable 
conditions, both Cf 1093 and Cf 1001 retained antiviral activ-
ity, fully comparable, or even greater, than that shown for 
ddA/ddl in primary macrophages not treated with M-CSF. 
Of interest is the observation that the selectivity index of 
the d4A aryloxyphosphoramidate prodrug is markedly in-
creased as compared to that of d4A itself. These data suggest 
that the toxicity of d4A, in contrast to that of ddA, is not 
mainly due to its eventual conversion to its 5'-triphosphate 
metabolite, but presumably to d4A itself (or a non-phos-
phorylated catabolite of d4A). The presence and/or the intra-
cellular formation of this toxic cellular substance must be 
substantially prevented by delivering the prodrug, and releas-
ing the d4A-MP derivative directly into, the intact cells. Addi-
tional studies are required to further clarify this issue. 
Although the antiviral activity and selectivity of the ddA 
and d4A aryloxyphosphoramidate prodrugs look highly 
promising in cell culture, no animal data on the pharmacol-
ogy, potential toxicity and antiviral efficacy of the drug are 
available so far to confirm their pronounced therapeutic index 
in vivo. 
It should also be mentioned that an improved antiviral 
activity of ddA has recently been observed for another pro-
drug approach (i.e., bis(S-acyl-2-thioethyl) or bis(SATE) de-
rivatives of ddAMP) [15]. As for the aryloxyphosphorami-
dates, the bis(SATE) prodrug approach could also be 
successfully applied to deliver ddAMP into the intact cells. 
However, both the aryloxyphosphoramidate and bis(SATE) 
approaches virtually failed to markedly improve the antiviral 
activity of ddl (Ref. [15] and our unpublished data). The ex-
planation for this phenomenon is most likely to be the differ-
ent pathways that are followed for the activation of both 
compounds. Whereas ddA and d4A are directly metabolized 
to ddAMP (and d4A-MP), prior to further metabolism to the 
5'-triphosphate derivatives, ddl has to be metabolised first to 
ddIMP, followed by a 2-step conversion to succinyl-ddAMP 
by succinyl-AMP synthetase and further on to ddAMP by 
succinyl-AMP lyase, before it can be processed to the 5'-tri-
phosphate. Therefore, direct delivery of ddIMP into the intact 
cells may only overcome the first activation (phosphorylation) 
step but not the subsequent two (poorly efficient) conversion 
steps to ddAMP. 
In conclusion, we have developed a highly successful ary-
loxyphosphoramidate prodrug approach to markedly improve 
the anti-HIV and anti-HBV activity of the purine nucleoside 
analogues, ddA and d4A. We have also shown that the selec-
tivity index of the ddA and d4A prodrugs can be markedly 
improved by such an approach, which opens up interesting 
and novel perspectives to optimize existing strategies and/or to 
develop new modalities for the treatment of both HIV and 
HBV infections. 
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